Telstar completes the expansion of Merck’s biotechnological manufacturing plant in Madrid

Merck has finished the enlargement of its facilities in Tres Cantos, Madrid, where the German company intends to increase the production of recombinant growth hormone (r-hGH) by 50% (available under the commercial brand Saizen). The biotechnological plant in Madrid produces 100% of the group's growth hormone.

The complete execution of the project, developed under the EPCM (Engineering, Procurement and Construction Management) contract model, has been carried out by Telstar. The company has developed the basic and detailed global engineering for the production area with its pharmaceutical and industrial services and the new office building, as well as purchase management, project and site management, including construction supervision.

All process installations and industrial services for this area have been carried out by Telstar. The company has also provided health and safety coordination services.

Telstar provided a team of 10 specialists, including pharmaceutical consultant and HVAC specialist engineers, and used the latest tools for BIM design (Revit and Plant 3D) for smart P&ID generation and the development of a virtual model.  Applying BIM tools enabled Telstar to devise an integral and conceptual visualisation of the project before carrying it out. This provided the experts with the knowledge to identify any potential risks and given them the information view and resolve technical problems before the construction started. Additionally, this has assisted with the introduction of functional, safety and aesthetic improvements in the early stages of the project.